Visual arrestin interaction with clathrin adaptor AP-2 regulates photoreceptor survival in the vertebrate retina

Hormoz Moaven1, Yukihiro Koike, Christine C Jao

  • 1Neuroscience Graduate Program, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

Insights

Visual arrestin (ARR1) binding to a mutated rhodopsin forms a toxic complex, driving retinal degeneration. A variant lacking AP-2 binding rescues vision, revealing ARR1

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Neuroscience

Background:

  • Arrestins bind activated G protein-coupled receptors (GPCRs), terminating G protein signaling.
  • Nonvisual arrestins can scaffold signaling molecules to internalized GPCRs, initiating G protein-independent signals.
  • Vertebrate visual arrestin (ARR1) terminates G protein signaling from light-activated rhodopsin, but its role in G protein-independent signaling is unclear.

Purpose of the Study:

  • Investigate the role of AP-2 recruitment by the K296E/ARR1 complex in retinal degeneration.
  • Determine if ARR1 contributes to G protein-independent signaling in the vertebrate retina.
  • Evaluate the therapeutic potential of an ARR1 splice variant lacking AP-2 binding.

Main Methods:

  • Measured binding affinity of ARR1 for AP-2.
  • Utilized a transgenic mouse model expressing a toxic rhodopsin mutation (K296E).
  • Assessed the effect of an ARR1 splice variant (p44) on retinal degeneration and visual function.

Main Results:

  • ARR1 binds AP-2 with low affinity, but high rod concentration favors interaction.
  • The K296E rhodopsin mutation forms a stable complex with ARR1, leading to retinal toxicity.
  • The p44 ARR1 variant, lacking AP-2 binding, prevented retinal degeneration and rescued visual function in K296E mice.

Conclusions:

  • ARR1 plays a unique role in a G protein-independent signaling cascade in the vertebrate retina.
  • The K296E/ARR1 complex, through AP-2 recruitment, initiates a cell death signal.
  • Targeting ARR1-AP-2 interaction or using protective variants like p44 offers a therapeutic strategy for retinitis pigmentosa.